All In MedTech

FDA Clearance Tracker · P230017-S009

PulseSelect™ Pulsed Field Ablation (PFA) system

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Feb 17, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Feb 17, 2026

Approved

Time to decision

102 days

Received Nov 7, 2025. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P230017-S009
Device name
PulseSelect™ Pulsed Field Ablation (PFA) system
Applicant location
Mounds View, MN
Received
Nov 7, 2025
Decided
Feb 17, 2026
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P230017

Device type

Device class
Class III

Every decision under product code QZI

FDA's approval statement

As written in FDA's record.

the PulseSelect System for an update for R-wave gating of PulseSelect Pulsed Field Ablation (PFA) energy deliveries to be made optional

Source documents

Other decisions for Medtronic, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

7 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.